Pharma boss warns UK risks squandering Trump trade deal

Bristol Myers Squibb chief executive Chris Boerner has warned that the UK risks squandering the value of its pharmaceutical trade deal with the Trump administration if promised reforms are not implemented quickly enough.

In an interview published by The Times on June 26, Boerner said the company still plans to go ahead with its promised $500 million investment in the UK over five years. But he said future decisions on where the drugmaker places capital will depend on whether Britain proves it is a competitive market for medicines.

Boerner said investment decisions are made globally and are shaped by whether a country effectively values medicines and offers a business environment that supports research, launches and long-term commitments.

What the deal was meant to do

The warning comes as the UK continues to work through the pharmaceutical side of its trade arrangement with the Trump administration, which was designed to improve access for drugmakers while giving US exporters tariff relief.

Earlier reporting described the deal as including a UK commitment to raise spending on innovative medicines from 0.3% to 0.6% of GDP by 2035. The arrangement also included a three-year tariff exemption for pharma exports to the US, in exchange for UK policy changes intended to make the market more attractive.

That bargain has been politically sensitive in Britain because officials have indicated the near-term cost will be borne by the Department of Health and Social Care and the NHS budget rather than the Treasury.

Budget pressure and policy change

In February, reporting said the first three years of the deal could cost about £1 billion in England. The government has since faced scrutiny over how it will absorb that spending while trying to keep medicines access and launch incentives competitive.

A central issue is how far ministers will move on drug pricing and appraisal rules, including the thresholds used by NICE. The government has also been criticised for slow progress in revising how the UK values innovative medicines.

Boerner’s intervention adds fresh pressure on ministers because it ties the trade deal directly to future commercial decisions. The message from BMS is that the UK may secure the headline investment already announced, but additional capital allocation will depend on whether the policy environment improves.

Launch decisions matter too

The stakes are not limited to investment. BMS has also signalled that launch decisions can be affected by the same policy backdrop, including the planned UK launch of its schizophrenia drug Cobenfy.

The company has delayed or threatened to withhold a UK launch for the medicine if conditions do not improve. That matters because prior reporting says UK patients can receive globally approved drugs around 20 months later than patients in some other markets.

Drugmakers argue that those delays weaken the UK’s appeal as a launch market and make it harder to justify investment in trials, manufacturing and commercial infrastructure.

Wider industry and NHS implications

The UK government has tried to present the deal as part of a broader life-sciences strategy, but the latest warning shows how fragile that case remains if companies do not see reform follow-through.

For the NHS, the risk is two-sided. Faster reform could help Britain attract launches and investment, but it may also intensify pressure on budgets if more is spent on newer medicines. That balance has been controversial since the deal was first reported.

The criticism has also fed into wider concerns about the role of NICE. In April, MPs objected to Wes Streeting’s new power over what the NHS pays for drugs, arguing that it weakens NICE’s independence.

Background to the pressure

The Trump administration’s tougher stance on drug pricing has shaped the environment in which these negotiations have taken place. In April, reporting described Donald Trump threatening a 100% tariff on drugmakers that did not strike deals to lower US prices, while offering exemptions in some cases for companies that agreed to pricing or manufacturing commitments.

That broader pressure helps explain why drugmakers are keen to secure predictable treatment in major markets. For the UK, the challenge is to persuade companies that it can still be a priority launch and investment destination even as it asks the health system to spend more on medicines.

Boerner’s warning suggests the answer will depend less on the headline agreement than on the speed and credibility of its implementation.

What happens next

The immediate questions are whether the UK government sets out a clearer timetable for the reforms linked to the deal, and whether BMS confirms any change in the timing or scale of its planned UK investment.

Another open question is whether Cobenfy is ultimately filed or launched in Britain if progress remains slow. Other large drugmakers will also be watching to see whether the UK follows through on the commitments attached to the trade deal, or whether the warning from BMS becomes a template for further public pressure.